Reactogenicity and immunogenicity of a double-strength acellular pertussis vaccine

Dean A Blumberg; Patricia C. Chatfield; James D. Cherry; Ricki G. Robinson; Kathleen Smith; Laura Mabie; H. James Holroyd; Leonard R. Baker; Frank E. Dudenhoeffer; Noelani Apau; Jill G. Hackell; Andrea Cawein

doi:10.1016/0264-410X(92)90442-M

Reactogenicity and immunogenicity of a double-strength acellular pertussis vaccine

Dean A Blumberg, Patricia C. Chatfield, James D. Cherry, Ricki G. Robinson, Kathleen Smith, Laura Mabie, H. James Holroyd, Leonard R. Baker, Frank E. Dudenhoeffer, Noelani Apau, Jill G. Hackell, Andrea Cawein

Research output: Contribution to journal › Article

2 Scopus citations

Abstract

The reactogenicity and immunogenicity of a double-strength acellular pertussis vaccine were evaluated after administration to 16 4-6-year-old children. The vaccine contained toxoided lymphocytosis-promoting factor (6.0 μg/dose), filamentous haemagglutinin (70 μg/dose), agglutinogens (1.4 μg/dose) and the 69 kDa protein (≈8.0 μg/dose). The vaccine was extremely well tolerated with few minor side effects following immunization. Significant increases in antibodies to all pertussis vaccine components were noted. In summary, this double-strength acellular pertussis vaccine, containing a very high dose of filamentous haemagglutinin, had minimal reactogenicity and was immunogenic. These findings, as well as other studies with this vaccine, indicate that filamentous haemagglutinin is not a major determinant of vaccine reactogenicity.

Original language	English (US)
Pages (from-to)	614-616
Number of pages	3
Journal	Vaccine
Volume	10
Issue number	9
DOIs	https://doi.org/10.1016/0264-410X(92)90442-M
State	Published - 1992
Externally published	Yes

Keywords

acellular vaccine
children
filamentous haemagglutinin
immunogenicity
Pertussis
reactogenicity

ASJC Scopus subject areas

Immunology
Microbiology
Virology
Infectious Diseases
Public Health, Environmental and Occupational Health
veterinary(all)

Access to Document

10.1016/0264-410X(92)90442-M

Fingerprint Dive into the research topics of 'Reactogenicity and immunogenicity of a double-strength acellular pertussis vaccine'. Together they form a unique fingerprint.

Cite this

Blumberg, D. A., Chatfield, P. C., Cherry, J. D., Robinson, R. G., Smith, K., Mabie, L., Holroyd, H. J., Baker, L. R., Dudenhoeffer, F. E., Apau, N., Hackell, J. G., & Cawein, A. (1992). Reactogenicity and immunogenicity of a double-strength acellular pertussis vaccine. Vaccine, 10(9), 614-616. https://doi.org/10.1016/0264-410X(92)90442-M

Reactogenicity and immunogenicity of a double-strength acellular pertussis vaccine. / Blumberg, Dean A; Chatfield, Patricia C.; Cherry, James D.; Robinson, Ricki G.; Smith, Kathleen; Mabie, Laura; Holroyd, H. James; Baker, Leonard R.; Dudenhoeffer, Frank E.; Apau, Noelani; Hackell, Jill G.; Cawein, Andrea.

In: Vaccine, Vol. 10, No. 9, 1992, p. 614-616.

Research output: Contribution to journal › Article

@article{7725c67f487c4437b740966d078675b7,

title = "Reactogenicity and immunogenicity of a double-strength acellular pertussis vaccine",

abstract = "The reactogenicity and immunogenicity of a double-strength acellular pertussis vaccine were evaluated after administration to 16 4-6-year-old children. The vaccine contained toxoided lymphocytosis-promoting factor (6.0 μg/dose), filamentous haemagglutinin (70 μg/dose), agglutinogens (1.4 μg/dose) and the 69 kDa protein (≈8.0 μg/dose). The vaccine was extremely well tolerated with few minor side effects following immunization. Significant increases in antibodies to all pertussis vaccine components were noted. In summary, this double-strength acellular pertussis vaccine, containing a very high dose of filamentous haemagglutinin, had minimal reactogenicity and was immunogenic. These findings, as well as other studies with this vaccine, indicate that filamentous haemagglutinin is not a major determinant of vaccine reactogenicity.",

keywords = "acellular vaccine, children, filamentous haemagglutinin, immunogenicity, Pertussis, reactogenicity",

author = "Blumberg, {Dean A} and Chatfield, {Patricia C.} and Cherry, {James D.} and Robinson, {Ricki G.} and Kathleen Smith and Laura Mabie and Holroyd, {H. James} and Baker, {Leonard R.} and Dudenhoeffer, {Frank E.} and Noelani Apau and Hackell, {Jill G.} and Andrea Cawein",

year = "1992",

doi = "10.1016/0264-410X(92)90442-M",

language = "English (US)",

volume = "10",

pages = "614--616",

journal = "Vaccine",

issn = "0264-410X",

publisher = "Elsevier BV",

number = "9",

}

TY - JOUR

T1 - Reactogenicity and immunogenicity of a double-strength acellular pertussis vaccine

AU - Blumberg, Dean A

AU - Chatfield, Patricia C.

AU - Cherry, James D.

AU - Robinson, Ricki G.

AU - Smith, Kathleen

AU - Mabie, Laura

AU - Holroyd, H. James

AU - Baker, Leonard R.

AU - Dudenhoeffer, Frank E.

AU - Apau, Noelani

AU - Hackell, Jill G.

AU - Cawein, Andrea

PY - 1992

Y1 - 1992

N2 - The reactogenicity and immunogenicity of a double-strength acellular pertussis vaccine were evaluated after administration to 16 4-6-year-old children. The vaccine contained toxoided lymphocytosis-promoting factor (6.0 μg/dose), filamentous haemagglutinin (70 μg/dose), agglutinogens (1.4 μg/dose) and the 69 kDa protein (≈8.0 μg/dose). The vaccine was extremely well tolerated with few minor side effects following immunization. Significant increases in antibodies to all pertussis vaccine components were noted. In summary, this double-strength acellular pertussis vaccine, containing a very high dose of filamentous haemagglutinin, had minimal reactogenicity and was immunogenic. These findings, as well as other studies with this vaccine, indicate that filamentous haemagglutinin is not a major determinant of vaccine reactogenicity.

AB - The reactogenicity and immunogenicity of a double-strength acellular pertussis vaccine were evaluated after administration to 16 4-6-year-old children. The vaccine contained toxoided lymphocytosis-promoting factor (6.0 μg/dose), filamentous haemagglutinin (70 μg/dose), agglutinogens (1.4 μg/dose) and the 69 kDa protein (≈8.0 μg/dose). The vaccine was extremely well tolerated with few minor side effects following immunization. Significant increases in antibodies to all pertussis vaccine components were noted. In summary, this double-strength acellular pertussis vaccine, containing a very high dose of filamentous haemagglutinin, had minimal reactogenicity and was immunogenic. These findings, as well as other studies with this vaccine, indicate that filamentous haemagglutinin is not a major determinant of vaccine reactogenicity.

KW - acellular vaccine

KW - children

KW - filamentous haemagglutinin

KW - immunogenicity

KW - Pertussis

KW - reactogenicity

UR - http://www.scopus.com/inward/record.url?scp=0026642329&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=0026642329&partnerID=8YFLogxK

U2 - 10.1016/0264-410X(92)90442-M

DO - 10.1016/0264-410X(92)90442-M

M3 - Article

C2 - 1502839

AN - SCOPUS:0026642329

VL - 10

SP - 614

EP - 616

JO - Vaccine

JF - Vaccine

SN - 0264-410X

IS - 9

ER -